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The FreeStyle Libre (FSL) flash glucose monitoring device was made available on the UK              
National Health Services (NHS) drug tariff in 2017. This study aims to explore the UK               
real-world experience of FSL and the impact on glycaemic control, hypoglycaemia,           
diabetes-related distress and hospital admissions. 
Methods 
Clinicians from 102 National Health Service hospitals in the United Kingdom submitted FSL             
user data, collected during routine clinical care, to a secure web-based tool held within the               
NHS N3 network. T-tests and Mann-Whitney-U tests were used to compare the baseline and              
follow-up HbA1c and other baseline demographic characteristics. Linear regression analysis          
was used to identify predictors of change in HbA1c following the use of FSL. Within-person               
variations of HbA1c calculated adj-HbA1c-SD=SD/sq. Root [n/ (n−1)]. 
Results  
Data were available for 10,370 (97% with Type 1 diabetes) FSL users; age 38.0 (±18.8)               
years, 51% female, diabetes duration 16.0 (±49.9) years, and BMI of 25.2 (±16.5) kg/m​2​. FSL               
users demonstrated a -5.5mmol/mol change in HbA1c, reducing from 67.5 (±20.9) (8.3%) at             
baseline to 62.3 (±18.5) (7.8%) mmol/mol after 7.5 (IQR=3.4-7.8) months of follow up             
(n=3182) (P<0.0001)). HbA1c reduction was greater in those with initial HbA1c ≥69.5            
(>8.5%) mmol/mol, reducing from 85.5mmol/mol (±16.1) (10%) to 73.1 mmol/mol (±15.8)           
(8.8%)) (P<0.0001). The baseline Gold score (score for hypoglycaemic unawareness) was           
2.7 (±1.8) and reduced to 2.4 (±1.7) (P<0.0001) at follow-up. 53% of those with a Gold                
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score of ≥4 at baseline had a score <4 at follow-up. FSL use was also associated with a                  
reduction in diabetes distress (P<0.0001). FSL use was associated with a significant            
reduction in paramedic callouts and hospital admissions due to hypoglycaemia and to            
hyperglycaemia/Diabetic Ketoacidosis (DKA). 
Conclusions  
We show that the use of FSL was associated with significantly improved glycaemic control              




Continuous glucose monitoring (CGM) is an established method of monitoring interstitial           
glucose levels to improve metabolic control in diabetes. The benefits include improvements            
in glycaemic control and hypoglycaemia[1-4]. ​Another form of interstitial glucose          
monitoring known as “flash” glucose monitoring (FreeStyle Libre; Abbott Diabetes Care)           
became available on the UK National Health Services (NHS) drug tariff in 2017. In contrast               
to CGM devices, the FSL does not have alarms to alert the user to hypo/hyperglycaemia.               
However, the advantages of FSL include lower costs and factory calibration, removing the             
need for frequent painful fingerstick calibrations during the 14-day wear period [5]. FSL is              
also known as intermittent continuous glucose monitoring (iCGM) as data from FSL sensor             
are only transmitted when the sensor is scanned with a reading device (reader or mobile               
phone app).  
Randomized controlled trials have demonstrated that FSL use is associated with a significant             
reduction in the incidence of hypoglycaemia in people with Type 1 and Type 2 diabetes, but                
to date, a reduction in HbA1c has not been reported [6-8]. However, several observational              
studies have reported improvements in glycaemic control[9-14]. There are no comprehensive,           
real-world, large population-based data sets looking at the impact of FSL on multiple aspects              
of diabetes care. In this study, we utilize data from the nationwide audit for FSL conducted                
by the Association of British Clinical Diabetologists (ABCD) to assess the patterns of use of               
FSL and to study its effect on glycaemic control, hypoglycaemia, diabetes-related distress            





Patient recruitment and data collection 
Data for this study were obtained from the nationwide audit of FSL conducted by ABCD               
(http://www.diabetologists-abcd.org.uk/n3/FreeStyle_Libre_Audit.htm). This nationwide   
audit was launched in November 2017. A secure online tool was launched in August 2018 on                
the National Health Services N3 network. NHS N3 network provides maximum security and             
allows analysis of anonymized national audit data The tool has the facility to detect data               
from the same patient entered in two sites (e.g. hospital and primary care) and to merge the                 
data when exported (centres and sites below). Data were collected at baseline and follow-up              
during routine clinical care (Appendix 1). Baseline pre-FSL data included demographics,           
source of FSL funding, previous structured education completion, HbA1c values from the            
previous 12 months, Gold score[15] (to assess hypoglycaemia awareness), severe          
hypoglycaemia, paramedics callouts and hospital admissions due to hyperglycaemia and          
DKA and hypoglycaemia over the previous 12 months. The Gold score is a 7-point              
questionnaire validated for identifying impaired awareness of hypoglycaemia (IAH); Gold          
score ≥4 determines IAH. 
We also collected diabetes-related distress scores at baseline and follow-up using the 2-item             
diabetes distress-screening instrument (DDS2) [16]. The DDS2 asks respondents to rate on a             
6-point scale the degree to which the following items caused distress: (1) “feeling             
overwhelmed by the demands of living with diabetes”, and (2) “feeling that I am often failing                
with my diabetes regimen”. At follow-up, we collected data on all the above along with FSL                
specific measures, such as the number of scans/day and time in range. At follow-up, we also                




The ABCD nationwide audit programme has Caldicott Guardian approval. The programme is            
an audit, not research. The NHS encourages audit of clinical practice, and there are              
guidelines, which were followed, in particular, that we only to collect data from routine              
clinical practice and analysis is of data, which is anonymized. 
Statistical Methods 
For reporting all the study outcomes, including HbA1c, GOLD score, and paramedic outcalls             
and hospital admissions, we restricted the statistical analysis to those with at least one              
follow-up. The chi-squared test of association was used to compare categorical variables, and             
the ​Mann–Whitney-​U​ test ​or t-tests were used to compare continuous variables before and            
after the use of FSL. An analysis stratified by various strata of age, baseline body mass index                 
(BMI), duration of diabetes, baseline HbA1c and gender looking at pre and post-FSL HbA1c              
and Gold score[15] and diabetes-related distress screening score (DDS)[16] were performed           
to understand the usefulness of FSL across these subgroups.  
To identify independent predictors of HbA1c reduction in response to use, change in the              
post-FSL HbA1c was modelled as an independent variable with an average of the pre-FSL              
HbA1c, age, gender, BMI, duration of diabetes, baseline BMI and number of FSL scans and               
structured diabetes education as independent predictors. The follow-up period was defined as            
the difference between the time of FSL initiation and the date of the most recent HbA1c                
measurement. The comparison of hospital admissions and paramedic callouts were also           
restricted only to patients with at least one follow-up. To investigate the effects of              
intra-individual variations of HbA1c with FSL use, we calculated the intra-individual mean            
(HbA1c-MEAN) and standard deviation (HbA1c-SD), respectively. HbA1c values obtained         
prior to FSL initiation of FSL and follow-up values post FSL were used. The inter-individual               
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difference in the number of HbA1c assessments was adjusted according to the formula:             
adj-HbA1c-SD=SD/√[n/(n−1)] as previously described [16]. All the statistical analysis were          
done in R 3.6.3 (​http://www.R-project.org/​). 
Results 
Demographic characteristics of the study population 
The available data ​from the study participants started on FSL are shown in ​Figure 1​. Baseline                
demographics, indications for starting FSL, structured education completion, and funding for           
FSL were available for 10,370 study participants from 102 National Health Services hospitals             
across the United Kingdom. Baseline HbA1c, Gold score and Diabetes Distress score were             
recorded for 9,968, 8737 and 8320 patients, respectively, while follow-up data were available             
for 3182, 2801 and 2532 patients, respectively. ​Table 1 shows the baseline characteristics of              
the whole study population in comparison to those with at least one follow-up. The mean age                
of the study participants was 38.0 (±18.0) years with 51% females with a mean duration of                
diabetes 16.0 (±49.9) years and a mean baseline HbA1c of 69.8 (±18.2) (8.5%) mmol/mol              
and baseline BMI of 25.2 (±16.5) kg/m​2​. The majority of those in the study 10,058 (97%) had                 
Type 1 diabetes, while the remaining had Type 2 diabetes or other forms of diabetes.               
Structured education had been completed by 6764 (65%) of study participants; the majority             
of FSL users were NHS funded 7602 (73%). The baseline demographic characteristics in             
those with at least one follow-up were similar to the entire study cohort.  
Indications for starting FSL 
There were multiple indications for FSL initiation in the study population (Figure 2). The              
most common indication for starting FSL was the replacement of self-monitoring of blood             
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glucose (38.5%) followed by high baseline HbA1c (34.5%), frequent hypoglycaemia (21.7%)           
and fear of hypoglycaemia (20.2%).  
Effect on Glycaemic Control and HbA1c variability 
Across the entire study population, the mean HbA1c reduced from 67.5 (±20.9) to             
62.3(±18.5), and in those with baseline HbA1c >69.5, reduced from 85.5 (±16.1) to 73.2              
(±15.8). (​Figure 3A and 3B​). ​Table 2 shows baseline and follow-up HbA1c in various strata               
of age, duration of diabetes, baseline BMI and baseline HbA1c. The greatest reduction in              
HbA1c was seen in those with baseline HbA1c >69.5 (-12.4 mmol/mol) followed by females              
(-10 mmol/mol), the age range of 19-60 (-8.6 mmol/mol) and duration of diabetes <5years              
(-8.4 mmol/mol).  
Predictors of HbA1c reduction (Table 3) were higher baseline HbA1c (beta 0.37 (±0.1)             
P<0.0001), and greater number of FSL scans/day (beta 0.10 (±0.1) P<0.0001). Age, gender,             
BMI, structured diabetes education completion and duration of diabetes did not predict a             
change in HbA1c following FSL initiation. This model explained 29% variability (adjusted            
R-squared=0.29) in the change in HbA1c following FSL initiation.  
We did a subset analysis in patients with Type 1 diabetes on with insulin pump (n=862) with                 
both baseline and follow-up HbA1c data. In this subgroup of patients, the mean HbA1c              
reduced from 65.3(±13) (8.1%) to 60.2(±25) (7.7%) mmol/mol. When the analysis was            
restricted to those with an insulin pump and a baseline HbA1c of >=69.5 mmol of HbA1c,                
the baseline HbA1c reduced from 80.8(±11) (9.5%) to 70.1 (±13) (8.6%).  
To understand the effect of the number of FSL scans on the change in glycaemic control we                 
stratified the patients into two groups, Group 1, those with ≥10 scans per day and Group 2,                 
those with less than ten scans per day. The baseline HbA1c reduced from 71.8 (±17) (8.7%)                
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to 66.5 (±15) (8.2%) in group 1 while it reduced from 63.5 (±14) (8%) to 57.9 (±21) (7.4%)                  
in group 2. The absolute drop in HbA1c was more significant in those with higher baseline                
HbA1c of >=69.5 with a reduction in HbA1c from 82.1 (±11) (9.7%) to 66.9 (±12) (8.3%) in                 
Group 1 and reduction in HbA1c from 85.2 (±16) (9.9%) to 75.8 (±15) (9.1) in Group 2. 
The median number of HbA1c readings in the year pre- FSL were 2 (IQR=2-4), and               
post-FSL HbA1c were 1 (IQR=1-3). The HbA1c variability, calculated as the adjusted            
standard deviation for HbA1c, reduced significantly from pre-FSL use to 24 (±14) to             
post-FSL 23 (±12) (P =0.01).  
Effect on self-reported Hypoglycaemia awareness  
In the entire study population, the baseline Gold score was 2.7 (±1.8), which reduced to 2.4                
(±1.7) (P<0.0001) at follow-up. ​Table 2 shows baseline and follow-up Gold score in various              
strata of age, duration of diabetes, baseline BMI and baseline HbA1c. The greatest             
improvement in Gold score following FSL was seen in those with age >60 years, a longer                
duration of diabetes, lower BMI and lower HbA1c. In those with paired baseline and              
follow-up data, 53% of those with baseline Gold score of ≥4 reported a score of <4 at                 
follow-up (regaining hypoglycaemia awareness), while 5% of those with baseline Gold score            
of <4 reported a follow-up score of ≥4 (IAH). We did an analysis in patients with Type1                 
diabetes on with insulin pump (n=862) with both baseline and follow-up GOLD score             
(n=1145). In this subgroup of patients, the GOLD score reduced from 2.75 (±1.6) 2.49 (±1.6). 
Diabetes Distress Score 
The mean DDS1 (feeling overwhelmed with demands of living with diabetes) significantly            
improved from 2.9 at baseline to 2.2 at follow-up (P<0.0001) and the mean DDS2 (feeling               
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that I am often failing with my diabetes routine) improved significantly from 3.0 to 2.2 at                
follow-up (P<0.0001) (​Figure 4​) 
FSL use, Time in Range (TIR), user-experience and side effects 
At follow up 89% reported FSL use >70% of the time with a mean of12.9(±14.1) scans per                 
day and mean captured sensor data of 87(±16) %.  
Of those with both follow-up HbA1c and TIR data (n=2191), in only 343 (15%) of cases did                 
clinicians report on the internationally accepted TIR (3.9-10mmol/l; 70 to 180mg/dl), with a             
median TIR of 43% (27%-56%).  
With the use of FSL, 68% of patients said that they detected a greater proportion of time in                  
hypoglycaemia, while 80% said that they were able to reduce the proportion of time in               
hypoglycaemia. With regards to the rate of hypoglycaemia 85% of the patients were able to               
reduce to rate of hypoglycaemia (56% said “a little less”, and 29% said “a lot less”) and 75%                  
were able to reduce the rate of nocturnal hypoglycaemia (45% said “a little less”, and 30%                
said “a lot less”). Of the 3,182 patients with follow-up 358 patients (11%) reported problems               
with FSL; of these, 224 (7%) had technical problems concerning the sensor or the device. 101                
patients (3%) reported itching, redness, rash or allergic reaction while 33 patients (1%)             
reported bleeding at the site of the device. 
 
Severe hypoglycaemia, paramedic callouts and hospital admissions  
These analyses were restricted to those who had both baseline and follow-up events recorded              
on the audit form. Comparing the 12-month pre-FSL with 7.5 ( IQR=3.4-7.8) months (range              
0.3-to 64 months​) of follow up in this cohort, the total number of paramedic call outs                
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(n=1940) decreased from 275 to 38 while the total number of hospital admissions due to               
hyperglycaemia/DKA (n=1978) decreased from 269 vs 86 following FSL and the number of             
admissions due to hypoglycaemia (n=1952) decreased from 120 vs 45 following FSL            
initiation. In the adult cohort, the total number of episodes of severe hypoglycaemia (n=1944)              
defined as those requiring third party assistance reduced from 1032 to 237; the total number               
of people with at least one episode of severe hypoglycaemia at baseline was 357 which               
reduced 104 at follow-up. (​Figure 5​). 
In a prorated analysis by month, with the use of FSL, the number of hyperglycaemia & DKA                 
reduced from 22/month to 11/month; the number of hypoglycaemia related admissions           
reduced from 10/month to 6/month; paramedic callouts reduced from 22/month to 5/month            
and episodes of severe hypoglycaemia reduced from 86/month to 31/month 
In a sensitivity analysis restricted to those with 12 months follow-up (n=409); the number of               
paramedics callouts for hypoglycaemia decreased from 83 to 4 following FSL, the number of              
hospital admissions due to hyperglycaemia/DKA decreased from 38 to 30, and the number of              
hospital admissions due to hypoglycaemia decreased by 27 to 2 following FSL initiation. 
 
Discussion 
We present the analysis of the largest real-world dataset from the nationwide study of flash               
glucose monitoring (FSL) in people with Type1 diabetes in United Kingdom (UK). We show              
that FSL use is associated with improved glycaemic control, hypoglycaemia awareness,           
reduced diabetes-related distress and reduced hospital admissions. In this large observational           
study, FSL use was associated with significant improvements in glycaemic control, especially            
in those with a higher baseline HbA1c and in those with a greater number of scans/day.                
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While several randomized controlled trials (RCT) for CGM have shown improved glycaemic            
control in those with Type 1 diabetes, to date, there are no RCT data which demonstrate a                 
reduction in HbA1c through FSL use. The SELFY study, a single-arm paediatric study,             
showed enhanced glucose time in range (TIR) and a 4.4 mmol/mol reduction in HbA1c              
compared to SMBG after an eight-week follow-up period. The IMPACT trial[8], primarily            
designed to assess the effect of FSL use on hypoglycaemia in those with well-controlled Type               
1 Diabetes, demonstrated a significant reduction in hypoglycaemia but no significant change            
in HbA1c, a likely reflection of the low baseline HbA1c (50 mmol/mol). The findings of our                
study are in keeping with the IMPACT study in terms of reported reductions in              
hypoglycaemia. We also found a less substantial change in HbA1c in those with a lower               
baseline HbA1c and is in agreement with previous studies which have reported a more              
beneficial effect of FSL in those with higher baseline HbA1c[12, 14]. 
The findings of our study are also in agreement with a recent meta-analysis[9] of 1,723                
participants with type 1 or type 2 diabetes which showed similar reductions in HbA1c              
following FSL use. This meta-analysis also demonstrated that the change in HbA1c with FSL              
use is highly correlated with baseline HbA1c. A real-world study of 900 FSL users from               
Edinburgh by Victoria Tyndall et al.[12], demonstrated a -4mmol/mol reduction in HbA1c            
overall and similar to our findings they observed a more substantial reduction in HbA1c in               
those with a higher baseline HbA1c and also those with a higher number of scans per day at                  
follow up. Overall, these results confirm the findings from clinical trials showing that the              
degree of engagement with the FSL device is an independent predictor HbA1c response in              
people with diabetes. 
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In this study, FSL use was associated with a significant reduction in HbA1c-variability during              
the follow-up period of 7.5 months, as seen in randomized controlled trials with CGM. Since               
HbA1c variability is associated with both micro[17, 18] and macro-vascular complications, at            
least in people with type 2 diabetes[19], if this pattern is sustained it is possible that FSL may                  
be associated with reduced complication rates in due course, beyond the benefits from the              
described reduction in HbA1c.  
The FSL has been shown to reduce the amount of time spent in hypoglycaemia in people with                 
Type 1 diabetes and Type 2 diabetes in RCT and observational data. In this study, we used                 
the Gold score to assess hypoglycaemia awareness. Following the use of the FSL, the Gold               
score reduced significantly; almost half who had a Gold score of ≥4 at baseline had               
restoration of hypoglycaemia awareness at follow-up, which may be a reflection of the             
significant reductions in self-reported hypoglycaemia. However, our findings are in contrast           
with a previous observational study[12], which showed no improvement in Gold score or the              
proportion with impaired awareness of hypoglycaemia as assessed by the Gold score. This             
may reflect the higher proportion of individuals with impaired awareness of hypoglycaemia            
(25% vs 13%) and higher baseline Gold score (2.7 vs 2) in our cohort. We observed                
significant improvements in both components of the Diabetes Distress score (2-item diabetes            
distress-screening instrument) in those who started on FSL. A recent study[12] described            
improvements in diabetes-related distress but a paradoxical increase in the anxiety and            
depression on the Hospital Anxiety and Depression Scale (HADS) in those using FSL. This              
could potentially reflect the demands which access to continuous glucose data places on an              




We report significant reductions in paramedic call out, and hospital admissions with the use              
of FSL in the 7.6 months follow-up period. The most significant reductions were seen in               
paramedic callouts followed by admissions due to hyperglycaemia/DKA, and those due to            
hypoglycaemia. These findings are consistent with the data reported from the Edinburgh            
cohort[12] and Belgian cohort[14]; however, a long-term follow-up and cost-effectiveness          
analysis are needed to evaluate the long-term clinical and economic benefits.  
Our study has several limitations. The data for this study were obtained from a national-wide               
audit of FSL of routine clinical care and as such, lacked a comparator arm and the                
methodically controlled data collection in RCTs. Nonetheless, these data represent the largest            
nationwide, real-world experience with FSL in all aspects of diabetes care. Most of our study               
participants consisted of people with Type 1 diabetes who fulfilled the criterion set by NHS               
England, funded by the National Health Service (NHS) the UK. The majority received NHS              
funding for their FSL device. The access criteria have resulted in ~1/3 of people living with                
diabetes being reimbursed for the FSL, which gives an indication of our representative             
selection criterion. The mean HbA1c at baseline was 69.8 mmol/mol (8.5%) in comparison to              
our national audit data which shows a mean Hba1c of 64mmol/l (8%) for pump users and                
71mmol/l (8.6%) for those on MDI. The study participants were, therefore, as the wider              
group of people with Type 1 diabetes in the United Kingdom. The average baseline HbA1c in                
our real-world study was higher as compared to the IMPACT trial[8] and the FUTURE              
study[14]. However, this reflects the real-world nature of the study, which report HbA1c             
values like our national HbA1c data. 
Our study may also be affected by regression to mean in HbA1c measures [20], a tendency                 
for HbA1c to fall on repeat testing. However, we have minimized this effect by taking an                
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average of available HbA1c measures one year prior to FSL use and including all HbA1c               
measures available during the follow-up period. We compared the paramedic callouts and            
hospital admissions, one year before starting FSL with the paramedic call out and hospital              
admissions in seven and half month’s follow-up period. However, we have also done a              
sensitivity analysis in a subset of patients with a twelve-month follow-up period and show              
that the beneficial effects of FSL persist for key outcomes. Given the significant reduction in               
the episodes of severe hypoglycaemia and paramedic callouts, these findings will have            
implications for morbidity and mortality related to diabetes and further studies are needed to              
confirm these. 
In summary, we report an analysis of the largest real-world dataset observing FSL use in               
Type 1 Diabetes and show that its use is associated with significant improvements in              
glycaemic control, hypoglycaemia awareness, severe hypoglycaemia and a reduction in          
hospital admissions. Long term follow-up and cost-effectiveness analysis are needed to           
assess if these benefits from FSL are sustained and affordable to health care systems. 
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Table 1: Baseline demographic characteristics of study participants with and without           
follow-up  
 Baseline data in all study participants 
(n=10,370) 
Baseline data in p
(n
Age (years) 38.0 (±18.8) 39.
Gender (% Females)  5322 (51%) 168
Baseline BMI 25.2 (±6.4) 25
Duration of Diabetes 16.0 (±49.9) 17 
Type 1 Diabetes (%) 10058 (97%) 312
Insulin Pump 2428 (23%) 86
British citizens(%) 8524 (82%) 271
NHS funded 7602 (73%) 235
Number of tests strips used per day 7.7 (±9.8) 8.1
Mean Pre-FSL HbA1c 69.8 (±18.2) 67.
Baseline Gold score 2.7(±1.8) 2.






 Pre FSL HbA1c Post- FSL HbA1c P-value Pre FSL-GOLD
score 
All 69.8(±18.2) 62.3(±18.5) <0.0001 2.7(±1.8) 
Age     
<=18 63.3(±19.02) 58(±14.9) <0.0001 NA 
19-60 71.3(±17.5) 62.7(±31) <0.0001 2.5(±1.7) 
>60 65.3(±13.5) 60.4(±11.4) <0.0001 3.1(±1.9) 
Gender     
Male 69.1(±18.5) 61.9(±22.4) <0.0001 2.70(±1.7) 
Female 70.4(±17.8) 60.0(±14.7) <0.0001 2.7(±1.7) 
Baseline BMI     
<=25 69.7(±19.9) 62.6(±23.5) <0.0001 2.8(±1.6) 
25-30 69.3(±13.8) 61.8(±16.9) <0.0001 2.6(±1.7) 
>30 70.6(15.3) 63.4(±13.7) <0.0001 2.6(±1.7) 
Duration of Diabetes     
<-5 68.8(±19.7) 60.4(15.0) <0.0001 (±1.7)2.69 
5-15 years 73.1(±19.3) 66.9(±28.4) <0.0001 2.44(±1.6) 
>15 years 68.4(±16.6) 61.2(±12.7) <0.0001 2.89(±1.8) 
Baseline HbA1c     
<=69.5 57.7(±7.7) 56.2(±17.4) <0.0001 2.8(±1.7) 
>69.5 85.5(±16.0) 73.1(±15.8) <0.0001 2.5(±1.7) 
Diabetes Education     
Yes 68.3(±16.2) 61.7(±19.2) <0.0001 2.7(±1.7) 
No 72.6(±21.2) 63.8(±16.3) <0.0001 2.8(±1.7) 
Table 2: ​Baseline and post-FSL HbA1c and GOLD score in various strata of age, duration of                
diabetes, baseline BMI and baseline HbA1c 
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Table 3: ​Linear regression model showing predictors of decline in HbA1c following the use              
of FSL 
 
 Beta SE P-value 
Pre FSL HbA1c 0.37 0.01 <0.0001 
Number of FSL scans 0.10 0.01 <0.0001 
Completion of Structured Education 0.82 0.48 0.090 
Age -0.02 0.01 0.153 
Baseline BMI 0.04 0.04 0.237 
Gender -0.30 0.42 0.483 









Figure 1 Title​: Study schematic showing data for HbA1c, Gold score and Diabetes Distress 
Screening score in the ABCD nationwide audit of FSL 
Figure 1 legend:  Study Schematic showing the number of patients recruited in the study and 
sample size those with follow-up for HbA1c,  Gold score and Diabetes distress score 
Figure 2 Title​: Indications for starting FSL in the ABCD nationwide audit of FSL 
Figure 2 legend:   Figure 2 shows multiple indications for FSL initiation in the study 
population 
 
Figure 3a and 3b Title​: Distribution of HbA1c change pre and post FSL use in the ABCD                 
nationwide audit of FSL 
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Figure 3a and 3b legend:  Figure 3a and 3b shows the change in the HbA1c in the study 
population following FSL initation and in those with a baseline HbA1c of ≥ 69.5 
 
Figure 4​: Diabetes Distress Screening score before and after use of FSL in the ABCD               
nationwide audit of FSL 
Figure 4 legend:  Figure 4 shows the change in the two components of the Diabetes Distress 
Screening score before and after FSL initiation. The DDS2 asks respondents to rate on a 
6-point scale the degree to which the following items caused distress: (1) “feeling 
overwhelmed by the demands of living with diabetes”, and (2) “feeling that I am often failing 
with my diabetes regimen”. 
 
Figure 5​: Total number of Paramedic call outs, severe hypoglycaemia and hospital            
admissions during the 12months before and the 7.5 months of follow up using FSL in the                
ABCD nationwide audit  
Figure 5 legend​: Figure 5 shows the   change in Type 1 diabetes related  resource  utilization 
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